<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02609308</url>
  </required_header>
  <id_info>
    <org_study_id>OR15-008</org_study_id>
    <nct_id>NCT02609308</nct_id>
  </id_info>
  <brief_title>Lateral Ankle Sprain and Platelet Rich Plasma</brief_title>
  <official_title>Platelet Rich Plasma and Lateral Ankle Sprain. A Comparative Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad Autonoma de Nuevo Leon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidad Autonoma de Nuevo Leon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lateral ankle sprains are one of the most common in sports medicine. Considering the sprains
      in general, they represent an 85% of the ankle lesions. The incidence in high performance
      athletes range from 16 to 21%. It is estimated that 10,000 to 25,000 peoples suffers a
      lateral ankle sprain per hour in the United States. The objective of the treatment is to
      normalize the articular function and allow the patient to return to his or her normal
      physical activities. Platelet rich plasma is a simple of autologous blood with concentrations
      of platelets above baseline values. This is rich in platelet derived growth factor which
      stimulates cell replication, angiogenesis, transforming growth factor B1, fibroblast growth
      factor, epidermal growth factor, and insulin like growth factor. The risks of its
      applications are minimal and are usually involved with allergic reactions to other
      medications that are applied in combination with the platelet-rich plasma.

      To establish that the use of platelet rich plasma and immobilization with a short leg cast in
      acute lateral ankle sprains will enhance an early recovery in comparison with just
      immobilization with the cast.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lateral ankle sprains are one of the most common in sports medicine. Considering the sprains
      in general, they represent an 85% of the ankle lesions. The incidence in high performance
      athletes range form 16 to 21%. It is estimated that 10,000 to 25,000 suffers a lateral ankle
      sprain per hour in the United States. The objective of the treatment is to normalize the
      articular function and allow the patient to return to his or her normal physical activities.

      The lateral ligamentous complex of the ankle consists of three ligaments: the anterior
      talofibular, the calcaneofibular, and the posterior talofibular. The anterior talofibular
      ligament is the most affected. The patient describes a tear sensation in the ankle after an
      acute inversion of it. The injuries occur during physical activities as running. The patients
      presents with pain, swelling and tenderness over the affected ligaments. The proper diagnosis
      of the sprain includes anteroposterior, lateral and mortise view X rays of the affected
      ankle; if there is any suspicion of instability of the ankle, the physician shall order a
      Magnetic Resonance Image (MRI) to evaluate the ligaments.

      Lateral ankle sprains have been classified by numerous methods. By anatomic site, lateral
      ankle sprains can be classified as grade I: anterior talofibular sprain, grade II: anterior
      talofibular and calcaneofibular sprains, and grade III: anterior talofibular, calcaneofibular
      and posterior talofibular sprains. By clinical system the sprains can be classified as mild
      with minimal function loss, no limp, minimal swelling, tenderness, pain with reproduction of
      mechanism of injury; moderate with moderate functional loss, unable to rise on toes, limp
      when walking, localized swelling; and severe with diffuse tenderness, patient use crouches
      for ambulation.

      Conventional treatment for lateral ankle sprains is conservative, but a 32% of the patients
      have chronic complications as edema, pain, and ankle instability. The treatment for acute
      sprains have good to excellent results. Ankle dorsiflexion allows the fibers of the affected
      ligament to approximate and gives stability of the ankle. The first phase of the treatment
      requires rest, immobilization, compression with orthesis, and the use of non steroidal
      anti-inflammatory drug.

      Platelet rich plasma is a sample of autologous blood with concentrations of platelets above
      baseline values, is rich in platelet derived growth factor which stimulates cell replication,
      angiogenesis, transforming growth factor beta-1, fibroblast growth factor, epidermal growth
      factor, and insulin like growth factor. The risks of its applications are minimal and are
      usually involved with allergic reactions to other medications that are applied in combination
      with the platelet rich plasma.

      Purpose To establish that the use of platelet rich plasma and immobilization with a short leg
      cast in acute lateral ankle sprains will enhance an early recovery in comparison with just
      immobilization with the cast.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2015</start_date>
  <completion_date type="Actual">February 2017</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Use of platelet rich plasma in patients with ankle sprain</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
    <masking_description>Application of autologous platelet-rich plasma</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>American Orthopedic Foot and Ankle Society Ankle-Hindfoot Scale (AOFAS)</measure>
    <time_frame>Sixth month</time_frame>
    <description>Scale that evaluates pain, function and alignment of foot. The best score is 100 points, and the worst score are 0 points.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale</measure>
    <time_frame>Sixth month</time_frame>
    <description>Evaluate the pain in a scale of 0 to 10, when 0 is no pain, and 10 is the worst pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Foot and Ankle Disability Index (FADI)</measure>
    <time_frame>Sixth month</time_frame>
    <description>The Foot and Ankle Disability Index (FADI) assesses activities such as standing, walking on flat or uneven surfaces, walking on inclines, and the length of time of walking without difficulty. It also includes a section for sports activities and ankle or foot pain (or both). The highest score is 136 points, indicating the best clinical situation, free of pain and limitations, while the lowest score is 0.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Ankle Injuries</condition>
  <arm_group>
    <arm_group_label>Short leg cast</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patients in this group will be immobilize with a short leg cast for 14 days, and later they will be able to do physical rehabilitation and will be evaluated with American Orthopedic Foot and Ankle Society´s Ankle Hindfoot scale and Foot and Ankle Disability Index.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Platelet-rich plasma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this group, the patients will be receive a single dose of autologous platelet-rich plasma, and will be immobilized with a short leg cast. Posteriorly, they will be evaluated with American Orthopedic Foot and Ankle Society´s Ankle Hindfoot scale and Foot and Ankle Disability Index.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Short leg cast</intervention_name>
    <description>Immobilization with short leg cast with a dorsiflexed foot for two weeks</description>
    <arm_group_label>Short leg cast</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Platelet-rich plasma</intervention_name>
    <description>Will be applied 5 mL of autologous platelet-rich plasma under the lateral malleolus, over the anterior talofibular ligament</description>
    <arm_group_label>Platelet-rich plasma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute lateral ankle sprain with no more of 48 hours of evolution

          -  First time lateral ankle sprain

          -  Grade 2 or 3

        Exclusion Criteria:

          -  Associated pathologies like diabetes mellitus, osteoarthritis, rheumatoid arthritis,
             ankylosing spondylitis, neurologic or psychiatric issues

          -  Pregnant women

          -  Previous surgery of the foot and ankle

          -  Blood dyscrasias
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos Acosta-Olivo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidad Autonoma de Nuevo Leon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universidad Autonoma de Nuevo Leon</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>64480</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>van Dijk CN, Lim LS, Bossuyt PM, Marti RK. Physical examination is sufficient for the diagnosis of sprained ankles. J Bone Joint Surg Br. 1996 Nov;78(6):958-62.</citation>
    <PMID>8951015</PMID>
  </reference>
  <results_reference>
    <citation>Anderson RB, Hunt KJ, McCormick JJ. Management of common sports-related injuries about the foot and ankle. J Am Acad Orthop Surg. 2010 Sep;18(9):546-56. Review.</citation>
    <PMID>20810936</PMID>
  </results_reference>
  <results_reference>
    <citation>Bernuzzi G, Petraglia F, Pedrini MF, De Filippo M, Pogliacomi F, Verdano MA, Costantino C. Use of platelet-rich plasma in the care of sports injuries: our experience with ultrasound-guided injection. Blood Transfus. 2014 Jan;12 Suppl 1:s229-34. doi: 10.2450/2013.0293-12. Epub 2013 Jul 3.</citation>
    <PMID>23867186</PMID>
  </results_reference>
  <results_reference>
    <citation>Frei R, Biosca FE, Handl M, Trc T. [Conservative treatment using plasma rich in growth factors (PRGF) for injury to the ligamentous complex of the ankle]. Acta Chir Orthop Traumatol Cech. 2008 Feb;75(1):28-33. Czech.</citation>
    <PMID>18315959</PMID>
  </results_reference>
  <results_reference>
    <citation>Hall MP, Band PA, Meislin RJ, Jazrawi LM, Cardone DA. Platelet-rich plasma: current concepts and application in sports medicine. J Am Acad Orthop Surg. 2009 Oct;17(10):602-8. Review. Erratum in: J Am Acad Orthop Surg. 2010 Jan;18(1):17A.</citation>
    <PMID>19794217</PMID>
  </results_reference>
  <results_reference>
    <citation>Halpern BC, Chaudhury S, Rodeo SA. The role of platelet-rich plasma in inducing musculoskeletal tissue healing. HSS J. 2012 Jul;8(2):137-45. doi: 10.1007/s11420-011-9239-7. Epub 2012 Jan 18.</citation>
    <PMID>23874254</PMID>
  </results_reference>
  <results_reference>
    <citation>Hammond JW, Hinton RY, Curl LA, Muriel JM, Lovering RM. Use of autologous platelet-rich plasma to treat muscle strain injuries. Am J Sports Med. 2009 Jun;37(6):1135-42. doi: 10.1177/0363546508330974. Epub 2009 Mar 12.</citation>
    <PMID>19282509</PMID>
  </results_reference>
  <results_reference>
    <citation>Petersen W, Rembitzki IV, Koppenburg AG, Ellermann A, Liebau C, Brüggemann GP, Best R. Treatment of acute ankle ligament injuries: a systematic review. Arch Orthop Trauma Surg. 2013 Aug;133(8):1129-41. doi: 10.1007/s00402-013-1742-5. Epub 2013 May 28. Review.</citation>
    <PMID>23712708</PMID>
  </results_reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>November 17, 2015</study_first_submitted>
  <study_first_submitted_qc>November 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2015</study_first_posted>
  <results_first_submitted>September 29, 2017</results_first_submitted>
  <results_first_submitted_qc>September 30, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 23, 2019</results_first_posted>
  <last_update_submitted>September 30, 2019</last_update_submitted>
  <last_update_submitted_qc>September 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidad Autonoma de Nuevo Leon</investigator_affiliation>
    <investigator_full_name>Carlos A Acosta-Olivo</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>ankle sprain</keyword>
  <keyword>platelet-rich plasma</keyword>
  <keyword>ankle injuries</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sprains and Strains</mesh_term>
    <mesh_term>Ankle Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Short Leg Cast</title>
          <description>The patients in this group will be immobilize with a short leg cast for 14 days, and later they will be able to do physical rehabilitation and will be evaluated with American Orthopedic Foot and Ankle Society's Ankle Hindfoot scale and Foot and Ankle Disability Index.
Short leg cast: Immobilization with short leg cast with a dorsiflexed foot for two weeks.</description>
        </group>
        <group group_id="P2">
          <title>Platelet-rich Plasma</title>
          <description>In this group, the patients will be receive a single dose of autologous platelet-rich plasma, and will be immobilized with a short leg cast. Posteriorly, they will be evaluated with American Orthopedic Foot and Ankle Society's Ankle Hindfoot scale and Foot and Ankle Disability Index.
Platelet-rich plasma: Will be applied 5 mL of autologous platelet-rich plasma under the lateral malleolus, over the anterior talofibular ligament.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Short Leg Cast</title>
          <description>The patients in this group will be immobilize with a short leg cast for 14 days, and later they will be able to do physical rehabilitation and will be evaluated with American Orthopedic Foot and Ankle Society's Ankle Hindfoot scale and Foot and Ankle Disability Index.
Short leg cast: Immobilization with short leg cast with a dorsiflexed foot for two weeks.</description>
        </group>
        <group group_id="B2">
          <title>Platelet-rich Plasma</title>
          <description>In this group, the patients will be receive a single dose of autologous platelet-rich plasma, and will be immobilized with a short leg cast. Posteriorly, they will be evaluated with American Orthopedic Foot and Ankle Society's Ankle Hindfoot scale and Foot and Ankle Disability Index.
Platelet-rich plasma: Will be applied 5 mL of autologous platelet-rich plasma under the lateral malleolus, over the anterior talofibular ligament.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.5" spread="15.4"/>
                    <measurement group_id="B2" value="27.9" spread="12.1"/>
                    <measurement group_id="B3" value="26.7" spread="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.4" spread="3.8"/>
                    <measurement group_id="B2" value="26.8" spread="3.5"/>
                    <measurement group_id="B3" value="26.3" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Visual Analog Scale (VAS)</title>
          <description>The VAS assesses the pain level by assigning a score from 0 to 10, with 0 representing no pain and 10 representing the worst pain level.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.0" spread="1.3"/>
                    <measurement group_id="B2" value="7.5" spread="1.9"/>
                    <measurement group_id="B3" value="7.8" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>American Orthopedic Foot and Ankle Society Ankle-Hindfoot Scale (AOFAS)</title>
        <description>Scale that evaluates pain, function and alignment of foot. The best score is 100 points, and the worst score are 0 points.</description>
        <time_frame>Sixth month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Short Leg Cast</title>
            <description>The patients in this group will be immobilize with a short leg cast for 14 days, and later they will be able to do physical rehabilitation and will be evaluated with American Orthopedic Foot and Ankle Society's Ankle Hindfoot scale and Foot and Ankle Disability Index.
Short leg cast: Immobilization with short leg cast with a dorsiflexed foot for two weeks.</description>
          </group>
          <group group_id="O2">
            <title>Platelet-rich Plasma</title>
            <description>In this group, the patients will be receive a single dose of autologous platelet-rich plasma, and will be immobilized with a short leg cast. Posteriorly, they will be evaluated with American Orthopedic Foot and Ankle Society's Ankle Hindfoot scale and Foot and Ankle Disability Index.
Platelet-rich plasma: Will be applied 5 mL of autologous platelet-rich plasma under the lateral malleolus, over the anterior talofibular ligament.</description>
          </group>
        </group_list>
        <measure>
          <title>American Orthopedic Foot and Ankle Society Ankle-Hindfoot Scale (AOFAS)</title>
          <description>Scale that evaluates pain, function and alignment of foot. The best score is 100 points, and the worst score are 0 points.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.8" spread="2.6"/>
                    <measurement group_id="O2" value="98.5" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Analogue Scale</title>
        <description>Evaluate the pain in a scale of 0 to 10, when 0 is no pain, and 10 is the worst pain</description>
        <time_frame>Sixth month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Short Leg Cast</title>
            <description>The patients in this group will be immobilize with a short leg cast for 14 days, and later they will be able to do physical rehabilitation and will be evaluated with American Orthopedic Foot and Ankle Society's Ankle Hindfoot scale and Foot and Ankle Disability Index.
Short leg cast: Immobilization with short leg cast with a dorsiflexed foot for two weeks.</description>
          </group>
          <group group_id="O2">
            <title>Platelet-rich Plasma</title>
            <description>In this group, the patients will be receive a single dose of autologous platelet-rich plasma, and will be immobilized with a short leg cast. Posteriorly, they will be evaluated with American Orthopedic Foot and Ankle Society's Ankle Hindfoot scale and Foot and Ankle Disability Index.
Platelet-rich plasma: Will be applied 5 mL of autologous platelet-rich plasma under the lateral malleolus, over the anterior talofibular ligament.</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analogue Scale</title>
          <description>Evaluate the pain in a scale of 0 to 10, when 0 is no pain, and 10 is the worst pain</description>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.40"/>
                    <measurement group_id="O2" value="0.1" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Foot and Ankle Disability Index (FADI)</title>
        <description>The Foot and Ankle Disability Index (FADI) assesses activities such as standing, walking on flat or uneven surfaces, walking on inclines, and the length of time of walking without difficulty. It also includes a section for sports activities and ankle or foot pain (or both). The highest score is 136 points, indicating the best clinical situation, free of pain and limitations, while the lowest score is 0.</description>
        <time_frame>Sixth month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Short Leg Cast</title>
            <description>The patients in this group will be immobilize with a short leg cast for 14 days, and later they will be able to do physical rehabilitation and will be evaluated with American Orthopedic Foot and Ankle Society's Ankle Hindfoot scale and Foot and Ankle Disability Index.
Short leg cast: Immobilization with short leg cast with a dorsiflexed foot for two weeks.</description>
          </group>
          <group group_id="O2">
            <title>Platelet-rich Plasma</title>
            <description>In this group, the patients will be receive a single dose of autologous platelet-rich plasma, and will be immobilized with a short leg cast. Posteriorly, they will be evaluated with American Orthopedic Foot and Ankle Society's Ankle Hindfoot scale and Foot and Ankle Disability Index.
Platelet-rich plasma: Will be applied 5 mL of autologous platelet-rich plasma under the lateral malleolus, over the anterior talofibular ligament.</description>
          </group>
        </group_list>
        <measure>
          <title>Foot and Ankle Disability Index (FADI)</title>
          <description>The Foot and Ankle Disability Index (FADI) assesses activities such as standing, walking on flat or uneven surfaces, walking on inclines, and the length of time of walking without difficulty. It also includes a section for sports activities and ankle or foot pain (or both). The highest score is 136 points, indicating the best clinical situation, free of pain and limitations, while the lowest score is 0.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135.3" spread="1.0"/>
                    <measurement group_id="O2" value="135.4" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All included patients were evaluated at 24 weeks after the protocol interventions were initiated.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Short Leg Cast</title>
          <description>The patients in this group will be immobilize with a short leg cast for 14 days, and later they will be able to do physical rehabilitation and will be evaluated with American Orthopedic Foot and Ankle Society's Ankle Hindfoot scale and Foot and Ankle Disability Index.
Short leg cast: Immobilization with short leg cast with a dorsiflexed foot for two weeks.</description>
        </group>
        <group group_id="E2">
          <title>Platelet-rich Plasma</title>
          <description>In this group, the patients will be receive a single dose of autologous platelet-rich plasma, and will be immobilized with a short leg cast. Posteriorly, they will be evaluated with American Orthopedic Foot and Ankle Society's Ankle Hindfoot scale and Foot and Ankle Disability Index.
Platelet-rich plasma: Will be applied 5 mL of autologous platelet-rich plasma under the lateral malleolus, over the anterior talofibular ligament.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The diagnosis of Lateral Ankle Sprain was based on a clinical classification. We didn’t use an Ultrasound scan, to perform the application of the Platelet Rich Plasma, or to assess morphologically the affected area before and after the treatment</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Carlos Acosta-Olivo, PhD</name_or_title>
      <organization>Universidad Autónoma de Nuevo León</organization>
      <phone>+52 81 8347-3056</phone>
      <email>dr.carlosacosta@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

